JHVEPhoto Dear readers/followers, If you recall, I've been a vocal proponent of investing in Chemours (NYSE:CC) for some time. I even added it after my last article, which was published a few months back and which you can find here. Sometimes the stars line up, and you manage to "catch" a company at exactly the right place. Such was the case with Chemours during my last piece. That is why despite the recent downturn, my position in the company, and especially the one I bought at the time, is up over 22% com ...

The Chemours Company (CC) recently announced EVOLVE 2030 Version 2.0, the company's portfolio sustainability evaluation methodology. It assists Chemours in assessing its product offerings and development pipeline in reference to the United Nations Sustainable Development Goals (UN SDGs).The evaluation criteria help Chemours demonstrate progress toward its 2030 Corporate Responsibility Commitment target of generating 50% or more of its revenues from offerings that specifically contribute to the UN SDGs. The ...

A month has gone by since the last earnings report for Chemours (CC) . Shares have lost about 2.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Chemours due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Chemours' Earnings Beat, Revenues Miss Estimates in Q1 Ch ...

LOS ANGELES, May 17, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against The Chemours Company ("Chemours" or the "Company") (NYSE: CC). Class Period: February 10, 2023 – February 28, 2024 Lead Plaintiff Deadline: May 20, 2024 If you are a shareholder who suffered a loss, click here to participate. The complaint filed alleges that, throughout the Class Period, Defendants failed to dis ...

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against The Chemours Company ("Chemours" or the "Company") (NYSE: CC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Chemours and certain of its officers ...

财务数据和关键指标变化 - 公司第一季度合并净销售额约为14亿美元,较2023年同期的15亿美元下降6%,主要是由于APM和TSS的销量下降6%以及各业务线价格下降5% [24] - 合并调整后EBITDA从上年同期的3.04亿美元下降37%至1.93亿美元,主要是由于APM需求疲软和TSS年初表现较弱,部分被TT成本削减措施抵消 [25] - 合并净利润从上年同期的1.45亿美元下降至5200万美元,每股摊薄收益从0.96美元下降至0.34美元 [26] 各条业务线数据和关键指标变化 TT业务 - 第一季度净销售额下降7%至5.88亿美元,主要是价格下降7%,销量和汇率基本持平 [31] - 调整后EBITDA持平于7000万美元,EBITDA利润率提升100个基点至12%,主要是价格下降被TT转型计划带来的成本节约抵消 [33] - 与上一季度相比,净销售额下降10%,完全由销量下降驱动,调整后EBITDA增长9%,主要得益于将产品分配至收益更高的地区以及较低成本原料的时间性影响 [34] TSS业务 - 第一季度净销售额下降8%至4.49亿美元,主要是销量下降6%和价格下降2% [35] - 销量下降主要是泡沫、推进剂和其他产品组合需求疲软,部分被Opteon产品在固定制冷市场的需求增长所抵消 [35] - 价格下降主要是传统制冷剂价格受市场库存水平偏高影响,以及Opteon汽车OEM市场合同价格下降 [36] - 调整后EBITDA下降18%至1.51亿美元,利润率下降4个百分点至34% [37] - 与上一季度相比,净销售额增长20%,主要反映制冷剂产品组合的季节性强劲,部分被泡沫、推进剂和其他产品组合受建筑市场疲软的影响而有所下降 [38] APM业务 - 第一季度净销售额下降23%至2.99亿美元,主要是销量下降18%和价格下降5% [39] - 销量下降主要是经济敏感和非战略性终端市场需求疲软,以及之前披露的延长维修停产的尾部影响 [40] - 价格下降主要是产品组合和市场环境较去年同期疲软 [40] - 调整后EBITDA下降64%至3000万美元,利润率下降12个百分点至10% [41] - 与上一季度相比,净销售额下降8%,主要是高级材料产品组合需求持续疲软 [43] 公司战略和发展方向及行业竞争 - 公司正在推进TT业务转型计划,目标是成为全球最低成本的钛白粉生产商之一 [18][19][20][21] - 公司正在优化制造系统,提高生产效率,并提高自有矿石在TiO2生产中的利用率,这些措施已经带来了明显的成本节约 [19][20] - 公司正在投资于TSS业务的Opteon产品和新兴冷却技术,以把握监管驱动的低GWP解决方案转型机遇 [57][58][59][60][61][62][63][64][65][66][67][70] 管理层对经营环境和未来前景的评论 - 公司没有看到市场出现明显的触发因素,如利率下降、住宅建筑或汽车产量增加,但订单速度已恢复至2022年第三季度以来的最高水平,出现了一些补库存迹象 [13][14] - 公司预计第二季度合并净销售额和调整后EBITDA将同比增长约15%,TT和TSS业务有望实现中个位数的顺序增长,APM也有望实现接近30%的顺序EBITDA增长 [52][53][54][55] - 公司长期看好TSS业务,预计未来10年内将保持中高单位数的增长,调整后EBITDA率将保持在30%以上 [57][58][59][60][61][62][63][64][65][66][67][70][71] 问答环节重要的提问和回答 问题1 **Duffy Fischer 提问** 第一季度实际EBITDA与上次指引存在较大差异的原因是什么?公司对财务报告系统的准确性和及时性有何评价?公司对本季度指引中的一次性项目有何预期? [75][76][77][78][79][80] **Denise Dignam 和 Matt Abbott 回答** - 第一季度EBITDA高于预期的主要原因是:1)公司调整产品分配至收益更高的地区,2)原料成本时间性影响,3)TT转型计划持续产生强劲成果 [77][78][79] - 公司每月关闭账簿时才能获得实际制造成本数据,无法实时掌握供应链决策带来的成本变化 [79][80] - 公司预计第二季度的内部审查费用和环境修复费用将保持稳定,但股权激励费用和其他一次性费用将有所上升 [29][30] 问题2 **Hassan Ahmed 提问** 如果欧盟反倾销措施最终实施,这对公司TT业务会产生什么样的机会? [110][111][112][113][114] **Denise Dignam 回答** - 公司将继续专注于自身可控的因素,如降低成本,成为行业最低成本生产商,以及与客户建立可靠的合作伙伴关系 [111][112][113][114] - 反倾销措施可能会带来一些市场份额变化,但这可能是暂时的,公司将专注于自身的长期竞争力 [111][112] 问题3 **Mike Leithead 提问** 公司第二季度的净负债率是否会达到峰值?未来几个季度的负债情况如何? [118][119][120] **Matt Abbott 回答** - 第一季度末净负债率为3.7倍,公司预计上半年现金基本持平,下半年将出现经营现金流的改善,负债率将逐步下降 [119]

The Chemours Company (CC) logged profits of $52 million or 34 cents per share in first-quarter 2024, down from the year-ago quarter's profit of $145 million or 96 cents.Barring one-time items, earnings came in at 32 cents per share. It beat the Zacks Consensus Estimate of 25 cents.The company reported net sales of $1,350 million in the first quarter, down roughly 12% year over year. It fell short of the Zacks Consensus Estimate of $1,360.3 million. The downside was primarily attributed to a 23% decline in t ...

Chemours (CC) reported $1.35 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 12.1%. EPS of $0.32 for the same period compares to $0.98 a year ago.The reported revenue represents a surprise of -0.76% over the Zacks Consensus Estimate of $1.36 billion. With the consensus EPS estimate being $0.25, the EPS surprise was +28.00%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

Chemours (CC) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.98 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 28%. A quarter ago, it was expected that this chemical company would post earnings of $0.29 per share when it actually produced earnings of $0.31, delivering a surprise of 6.90%.Over the last four quarters, the company has ...

EXHIBIT 99.1 The Chemours Company Reports First Quarter 2024 Results Wilmington, Del., April 30, 2024 – The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies (“TT”), Thermal & Specialized Solutions (“TSS”), and Advanced Performance Materials (“APM”), today announced its financial results for the first quarter 2024. Key First Quarter 2024 Results • Net Sales of $1.4 billion, down 12% year-over-year • Net Income attribu ...